We report a novel use of transcatheter aortic valve replacement (TAVR) for valve-in-valve tricuspid valve replacement. A man in his 50s with prohibitive risks for surgical intervention underwent this procedure to improve severe, symptomatic tricuspid stenosis. Though current literature is limited to case reports, the Valve-in-Valve International Database (VIVID) reports similar mortality rates between surgical and transcutaneous replacement. As a novel, off-label procedure, there is limited operator experience. Nonetheless, in non-operative or high-risk patients, similar outcomes are noted in between transcatheter tricuspid valve replacement and surgical replacement. This registry sets the framework for further studies with the possibility of observing outcomes as operator experience increases, while highlighting the feasibility of the procedure.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528662 | PMC |
| http://dx.doi.org/10.1136/bcr-2022-251333 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Temporal trends of transcatheter aortic valve replacement outcomes in a high-volume center from China.
J Chin Med Assoc
November 2024
Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China.
Since the first transcatheter aortic valve replacement (TAVR) was performed in China in 2010, TAVR has developed rapidly. However, the temporal trends in the 1-year prognosis after TAVR in China have not been described. This study enrolled patients treated at a high-volume Chinese TAVR center, West China Hospital, between 2015 and 2022, to analyze and characterize the temporal trends in 1-year outcomes.
View Article and Find Full Text PDFPlatelet Volume Parameters as Predictors of Valvular Thrombosis Risk in Patients with Aortic and Mitral Valve Replacement.
Clin Appl Thromb Hemost
January 2025
Cardiovascular Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
Percutaneous valve implantation or surgical replacement with mechanical or biological valves are standard therapies for severe valvular heart diseases. Prosthetic valve thrombosis, though rare, is a serious complication, particularly with mechanical prostheses. This study aimed to investigate the predictive value of platelet volume parameters, including mean platelet volume (MPV), platelet distribution width (PDW), and platelet-large cell ratio (P-LCR), for valvular thrombosis risk in patients undergoing valve replacement therapy.
View Article and Find Full Text PDFProsthetic Valve Endocarditis After Y-Incision Aortic Annular Enlargement: A Simple Solution.
Ann Thorac Surg Short Rep
December 2024
Department of Cardiac Surgery, University of Michigan, Ann Arbor, Michigan.
The Y-incision aortic annular enlargement (AAE) has been established as a safe and effective technique for upsizing the aortic annulus by 3 to 4 valve sizes. However, concerns have been raised regarding its technical complexity during reoperations, particularly given the extensive enlargement of the aortic annulus and root. We present a case of reoperative aortic valve replacement after previous Y-incision AAE for prosthetic valve endocarditis and aortic root abscess.
View Article and Find Full Text PDFEarly Feasibility Study with the SATURN Transapical Mitral Valve Replacement Device.
Ann Thorac Surg Short Rep
December 2024
Department of Cardiac Surgery, San Raffaele University Hospital, Milano, Italy.
Purpose: To report the outcomes of the early feasibility study of transapical transcatheter mitral valve replacement (TMVR) with the SATURN System (InnovHeart, Milano, Italy) to treat patients with severe functional mitral regurgitation.
Description: Five high surgical risk patients underwent transapical transcatheter mitral valve replacement with the SATURN System at a single center. One-year follow-up is complete for all patients.
Long-Term Outcomes With Expanded Polytetrafluoroethylene Valved Conduits in Pediatric Patients.
Ann Thorac Surg Short Rep
December 2024
Institute for Integrated Life Skills, LLC, Bermuda Run, North Carolina.
Background: The expanded polytetrafluoroethylene (ePTFE) valved conduit (VC) has been reported for pulmonary valve replacement (PVR). The purpose of this study was to review long-term outcomes of our trileaflet ePTFE VC.
Methods: This multicenter study was performed with institutional review board approval from each institution.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!